人口药理动力学建模和Cefepime在重症儿科患者中的目标实现
Stephanie L Rolsma1,2,3, Marisa Blackman4, Cole Beck4
1Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Open forum infectious diseases
|March 2, 2026
概括
在重症儿童中优化塞费皮姆剂量至关重要. 延长或连续输注显著改善了药理动力学/药理动力学目标的实现,特别是对于耐药病原体.
科学领域:
- 儿科重症监护医学 儿科重症监护医学
- 药理动力学和药理动力学
- 传染性疾病 传染性疾病
背景情况:
- 塞费皮姆的剂量已为健康个体确立,但由于药理动力学变化,在重症儿童中理解程度较低.
- 优化cefepime剂量对于改善这种脆弱人群的治疗结果至关重要.
研究的目的:
- 为了优化cefepime在重症儿童的剂量策略.
- 评估不同输液持续时间对实现药理动力学/药理动力学目标的影响.
主要方法:
- 预计将重症儿童纳入接受cefepime的项目.
- 使用液体染色学-并联质谱学的群体药动力学 (popPK) 分析.
- 目标实现的概率 (PTA) 分析,包括体重和肌素清除.
主要成果:
- 一个具有比例误差的2分区模型,包括体重和肌素清除,最好地描述了cefepime的药理动力学.
- 长时间输注 (3小时或连续) 与较短的输注相比,产生了显著更高的cefepime断点.
- 较高的肌素清除率与目标实现的可能性降低有关.
结论:
- 治疗药物监测和popPK模型被推用于个性化的cefepime剂量在重症儿童.
- 延长和连续输注增强了cefepime的药理动力学/药理动力学目标,特别是对抗具有挑战性的病原体,如Pseudomonas aeruginosa.
- 这些优化剂量策略强烈推用于儿科重症监护病房.
更多相关视频
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
13.5K
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
7.8K
相关概念视频
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
340
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
340
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
388
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
388
01:27Pharmacodynamic Models: Overview
49
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
49
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
293
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
411
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
411
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
55
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
55